Importantly, the > 20-fold therapeutic window (IC50 > 50 μM in HER2-low NHDFs vs. 2.30 μM in T47D cells) supports tumor-selective delivery primarily driven by the EPR effect and pH-responsive release not HER2 overexpression. This evidence concerns the gene ERBB2 and neoplasm.